Change in growth differentiation factor 15, but not c-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Dominguez Rodriguez, Alberto ^a,b   Abreu Gonzalez, Pedro ^b,c   Hernandez Baldomero, Idaira F ^a   Avanzas, Pablo ^d   Bosa Ojeda, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Instituto Universitario de Tecnología Biomédicas   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH DIFFERENTIATION FACTOR 15; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIAC PATIENT; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION ACUTE CORONARY SYNDROME; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 84899978131     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/929536     Document Type: Article

References (17)

1. Sabatine M. S., Morrow D. A., de Lemos J. A., Gibson C. M., Murphy S. A., Rifai N., McCabe C., Antman E. M., Cannon C. P., Braunwald E., Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002 105 15 1760 1763 2-s2.0-0037117649 10.1161/01.CIR.0000015464.18023.0A (Pubitemid 34408881)
2. Lagrand W. K., Visser C. A., Hermens W. T., Niessen H. W. M., Verheugt F. W. A., Wolbink G.-J., Hack C. E., C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation 1999 100 1 96 102 2-s2.0-0033529379 (Pubitemid 29297946)
3. Ridker P. M., High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. The American Journal of Cardiology 2003 92 4B 166 171 2-s2.0-0141835079
4. Shi Y., Massagué J., Mechanisms of TGF- β signaling from cell membrane to the nucleus. Cell 2003 113 6 685 700 2-s2.0-0038682002 10.1016/S0092-8674(03)00432-X (Pubitemid 36724933)
5. Wollert K. C., Kempf T., Lagerqvist B., Lindahl B., Olofsson S., Allhoff T., Peter T., Siegbahn A., Venge P., Drexler H., Wallentin L., Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome. Circulation 2007 116 14 1540 1548 2-s2.0-34848820630 10.1161/CIRCULATIONAHA.107.697714 (Pubitemid 47511417)
6. Kempf T., Sinning J.-M., Quint A., Bickel C., Sinning C., Wild P. S., Schnabel R., Lubos E., Rupprecht H. J., Münzel T., Drexler H., Blankenberg S., Wollert K. C., Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the atherogene study. Circulation: Cardiovascular Genetics 2009 2 3 286 292 2-s2.0-70349679012 10.1161/CIRCGENETICS.108.824870
7. Hochholzer W., Morrow D. A., Giugliano R. P., Novel biomarkers in cardiovascular disease: update 2010. American Heart Journal 2010 160 4 583 594 2-s2.0-77957831897 10.1016/j.ahj.2010.06.010
8. Domínguez-Rodríguez A., Abreu-González P., Diurnal variations in biomarkers used in cardiovascular medicine: clinical significance. Revista Española de Cardiología 2009 62 11 1340 1341 10.1016/S0300-8932(09)73092-1
9. Dominguez-Rodriguez A., Tome M. C., Abreu-Gonzalez P., Inter-relation between arterial inflammation in acute coronary syndrome and circadian variation. World Journal of Cardiology 2011 3 2 57 58 10.4330/wjc.v3.i2.57
10. Fernández-Ortiz A., Pan M., Alfonso F., Comments on the ESC guidelines for the management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Española de Cardiología 2012 65 2 125 130 10.1016/j.recesp.2011.12.003
11. Dominguez-Rodriguez A., Abreu-Gonzalez P., Kaski J. C., Inflammatory systemic biomarkers in setting acute coronary syndromes-effects of the diurnal variation. Current Drug Targets 2009 10 10 1001 1008 2-s2.0-70450205127 10.2174/138945009789577963
12. Wollert K. C., Kempf T., Peter T., Olofsson S., James S., Johnston N., Lindahl B., Horn-Wichmann R., Brabant G., Simoons M. L., Armstrong P. W., Califf R. M., Drexler H., Wallentin L., Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007 115 8 962 971 2-s2.0-33847284450 10.1161/CIRCULATIONAHA.106.650846 (Pubitemid 46328289)
13. Damman P., Kempf T., Windhausen F., Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. International Journal of Cardiology 2014 172 2 356 363 10.1016/j.ijcard.2014.01.025
14. Anand I. S., Kempf T., Rector T. S., Tapken H., Allhoff T., Jantzen F., Kuskowski M., Cohn J. N., Drexler H., Wollert K. C., Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 2010 122 14 1387 1395 2-s2.0-77958507769 10.1161/CIRCULATIONAHA.109.928846
15. Eggers K. M., Kempf T., Wallentin L., Wollert K. C., Lind L., Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clinical Chemistry 2013 59 7 1091 1098 10.1373/clinchem.2012.201210
16. Kempf T., Zarbock A., Widera C., Butz S., Stadtmann A., Rossaint J., Bolomini-Vittori M., Korf-Klingebiel M., Napp L. C., Hansen B., Kanwischer A., Bavendiek U., Beutel G., Hapke M., Sauer M. G., Laudanna C., Hogg N., Vestweber D., Wollert K. C., GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine 2011 17 5 581 588 2-s2.0-79955703474 10.1038/nm.2354
17. Karakas M., Baumert J., Greven S., Rückerl R., Peters A., Koenig W., Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: results from the AIRGENE study. Clinical Chemistry 2010 56 5 861 864 2-s2.0-77951757953 10.1373/clinchem.2010.143719